Abl Bio Inc.

Yuhan Corporation

Kyeongsu Park

Yangsoon Lee

Hyejin Chung

Yeunju Kim

Eun-Jung Lee

Eunsil Sung

Eunyoung Park

Youngdon Pak

Donghoon Yeom

Kyungjin Park

Ui-Jung Jung

Moo Young Song

Byungje Sung

Jinhyung Ahn

Na Rae Lee

Yong-Gyu Son

Daehae Song

Young Bong Park

Eunjung Kim

Wonjun Son

Yeryoung Yong

Bora Lee

Juhee Kim

Jiseon Yoo

Jaehyun Eom

Jinwon Jung

Seawon Ahn

Uijung Jung

Minji Park

Hyoju Choi

Taewang Kim

YoungKwang Kim

Jaehyoung Jeon

Junhyun Jeong

Mikyung Chang

Sang-Jun Ha

Myeong Joon Kim

Chanmoo Lee

Junghyeon Hong

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Anti-BCMA antibody and use thereof

Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-HER2/anti-4-1BB bispecific antibody and use thereof

Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Anti-EGFR/anti-4-1BB bispecific antibody

The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Anti-ROR1 antibody and use thereof

Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Anti-B7-H3 antibody and use thereof

Growing community of inventors

Seongnam-si, South Korea

Kyeongsu Park